publication date: May. 10, 2019

Drugs & Targets FDA approves Kadcyla for breast cancer

FDA has approved Genentech’s Kadcyla (ado-trastuzumab emtansine) for adjuvant treatment of people with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and Herceptin (trastuzumab)-based treatment.

“This approval is a significant treatment advance for HER2-positive early breast cancer. By working closely with the FDA and participating in the Real-Time Oncology Review pilot program, we are able to make Kadcyla available for people with residual invasive disease after neoadjuvant therapy much sooner than anticipated,” Sandra Horning, chief medical officer and head of Global Product Development, said in a statement. “With every step forward in reducing the risk of disease recurrence, we come closer to the goal of helping each person with early breast cancer have the greatest opportunity for cure.”

The FDA rapidly reviewed and approved the application under the FDA’s Real-Time Oncology Review and Assessment Aid pilot programs, leading to an approval 12 weeks after completing the submission.

Kadcyla is the first Genentech medicine approved under the RTOR pilot program, which is exploring a more efficient review process to ensure safe and effective treatments are available to patients as early as possible.

For this indication, Kadcyla was also granted Breakthrough Therapy Designation, which is designed to expedite the development and review of … Continue reading FDA approves Kadcyla for breast cancer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.